politics
London Startup Poolbeg Pharma to Trial Drug Against Cancer Treatment Side-Effect
14 Haziran 2026The Guardian
- Poolbeg Pharma, a London-based startup, is set to trial a new drug called POLB 001 at six NHS hospitals. This oral medication aims to prevent cytokine release syndrome (CRS), a severe side effect associated with cancer immunotherapy that can lead to organ damage.
- In addition to this trial, the company is also developing a GLP-1 weight loss pill, indicating its broader focus on innovative treatments.
- Cytokine release syndrome is a known risk in patients undergoing immunotherapy for cancer, where the body's immune response can become dangerously exaggerated. The development of POLB 001 could not only mitigate this risk but also encourage more patients to pursue immunotherapy options that they might otherwise avoi…
- The initiation of trials for POLB 001 represents a significant step forward in addressing the complications associated with cancer immunotherapy. By targeting cytokine release syndrome, Poolbeg Pharma could enhance the safety and effectiveness of these treatments, potentially improving patient outcomes.
NewsAI özeti
This article is for informational purposes only and does not constitute medical advice. Always consult a healthcare professional for medical concerns.
Orijinal Kaynak
Tam teknik rapor ve canlı veriler için yayıncının web sitesini ziyaret edin.
Kaynağı Görüntüleİlgili Haberler
Tümünü Gör
NewsAI Mobil Uygulamaları
Her yerde okuyun. iOS ve Android için ödüllü uygulamalarımızı indirin.